Wednesday, March 15, 2017 - 11:00am to 1:00pm
Nanotechnology, the science of the very small, is rapidly evolving. It enables exciting improvements in many applications, and excipients are no exception! Pharmaceutical scientists, formulators, and excipient manufacturers have only just begun to explore the many ways for nanotechnology to improve drug delivery systems.
Even within the excipient/pharmaceutical industry, however, the principles and applications of nanotechnology are not necessarily familiar to stakeholders. Our expert presenters will bring you up to speed quickly on the basics of nanotechnology and its potential to, among other things, create new excipients and enhance existing ones.
The presenters will also discuss examples of nanoparticles which can enhance the efficiency of drugs as well as provide additional benefits offered for pharmaceutical development.
Learning / Awareness Objectives
At the completion of this webinar, you should be able to:
Identify how nanotechnology takes advantage of size
Identify how physical properties can impact the biological activity of nanoparticles
Discuss the regulatory environment for nanotechnology products
Discuss how nanotechnology can apply to excipients
Shaun F. Clancy, Ph.D.
Director of Product Stewardship, ESHQ Services North America
Shaun Clancy is Director of Product Stewardship for Evonik Corporation, the U.S. subsidiary of Evonik Industries of Germany. His focus at Evonik is on management of chemicals; communication of their hazards, exposures and risks; and how information on these topics are used to support product stewardship and compliance with pertinent laws. Shaun is a chemist, did his undergraduate work at the University of Buffalo, State University of New York and performed his doctoral studies at Northwestern University.
He chairs the American Chemistry Council's Health, Product & Science Policy Committee and represents Evonik on the ACC Nanotechnology Panel. He also represents Evonik on the Society of Chemical Manufacturers & Affiliates Chemical Risk Management Committee. Dr. Clancy is active in the International Organization for Standardization's Technical Committee 229 (ISO TC229) on Nanotechnologies, is the convener of Task Group 2 on Consumer & Societal Dimensions of Nanotechnology and is the US lead to Working Group 3 on Health, Safety and Environmental Aspects of Nanotechnologies. He participates in the Nanotechnology Committee of the Business & Industry Advisory Committee to the OECD, is the industry lead to the Working Party on Manufactured Nanomaterials (WPMN) Steering Group on Cooperation on Risk Assessment and Regulatory Programs and is also active in the Steering Group on Testing & Assessment.
Dr. Raymond David received his Ph.D. in Pharmacology from the University of Louisville, after which he was a Postdoctoral Fellow at the Chemical Institute of Toxicology in Research Triangle Park. Dr. David worked for 8 years at Microbiological Associates in Bethesda, Maryland where he managed the Inhalation and Mammalian Toxicology Departments. He also spent 14 years at Eastman Kodak in Rochester New York as Senior Toxicologist before joining BASF in 2006. Dr David has experience conducting inhalation, pulmonary, reproductive, and systemic toxicity studies. He led a team responsible for EH&S issues for nanotechnology at Eastman Kodak Company, and was responsible for nanotechnology issues at BASF Corporation from which he recently retired. He continues to work on nanotechnology issues in the ISO committee for nanotechnology. Dr. David has been board certified in General Toxicology since 1985. He is currently the principal at David Tox, LLC, a toxicology consulting company.